These findings indicate that RXRα suppresses generation of dry eye disease-inducing IL-17 producing lymphocytes s in the conjunctiva and identifies RXRα as a potential therapeutic target in dry eye. This evidence concerns the gene RXRA and Keratoconjunctivitis sicca.